ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 12
Examining Key Data from DAREON-8
Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).
Video content above is prompted by the following questions:
- DAREON-8: Phase 1 Clinical Trial of Combination Therapy with BI 764532, a DLL3 Targeting T-Cell Engager
- Please share your opinions of the therapeutic potential of Bl 764532, an lgG-like T-cell engager, for its ability to induce selective T-cell mediated tumor cell lysis when added to SOC (carboplatin + etoposide + atezolizumab) for previously untreated patients with ES-SCLC:
- Is a commercial molecular assay currently available to identify the presence of the delta-like ligand 3 notch receptor in patients with SCLC?
- Are you encouraged by an overall response rate of 28% and a 54% disease control rate in the Phase I trial?
- For which line of therapy do you envision BI 764532, if approved?
- Based on the exclusion criteria for the dose escalation trial, are you concerned that this agent may be associated with cardiovascular, cerebrovascular, and/or immunosuppressive TRAEs?
Related Content:
